European Medicines Agency (EMA), FDA and Health Canada have all issued warnings about the use of hydroxychloroquine & chloroquine in coronavirus, stating they should only be used in drug studies or hospitalized pts. https://t.co/HT39sT31Rq

American Hospital Association (AHA), in a new report, projected a loss of $202.6 billion from COVID-19 expenses and lost revenue for US hospitals and health systems from Mar 1 to Jun 30—about $50 billion in losses each month. https://t.co/pidOduwnDb

COVID-19 Does alot of Damage via thrombotic complications - a role for complement or autoantibody mediated thrombotic microangiopathy? #COVID19 https://t.co/33R8WxE5C0

Grand Rounds tomorrow at Rutgers - Im Lecturing on “Disease Modifying and Biologic Use for COVID-19 & the Cytokine Storm Syndrome” https://t.co/FYsr77a68Z Meeting ID: 934 0443 3549

“Middle-high level of RF-IgM could lead to false-positive reactivity of SARS-CoV-2 IgM “ As more people want SARS-CoV2 antibody testing, I am afraid this will give people a false sense of security ⁦@RheumNow⁩ ⁦@ACRheum⁩ NCBI - NLM - NIH https://t.co/vkjWRJQV27

Check out a great Grand Rounds by Dr. Len Calabrese @LCalabreseDO on "IL-6 in Health & Disease" - great 30 min lecture and great Q&A session - Bravo Lenny! https://t.co/eWTKotQya3

Case report of a stable GPA patient treated with pred and Rituxan on 3/5, developed COVID Sxs next day, progressed to high fever, resp failue, mech ventilaion, Rx with antivirals, HCQ; extubated day 20, negative PCR x2 and discharged day 29. https://t.co/SSSKRbYK2R

World Scleroderma Found Recs on COVID 1) SSc w/ Lung dz may be at risk; 2) Cont Rx & avoid SSc lapse in Rx; 3) SSc pts dont need testing unless Sx+; 4) ACE/ARBs BP meds continued; 5) Initiating preventative Rx w/ HCQ is not recommended https://t.co/8BUE6tLLTi

On May 1st the FDA issued "emergency use authorization" for intravenous use of Remdesivir in patients hospitalised with suspected/confirmed severe COVID-19 infection - defined as SpO2 ≤ 94%, need for O2, mech ventilation, or ECMO. https://t.co/XnBaclhPKm

Pilot study of COVID+ pts treated with antiviral therapy PLUS either Baricitinib or HCQ x2wks shows no changes in clinical/lab outcomes with HCQ/v but better outcomes with Bari for death (0 v 4), CRP *8-->1mg/dl) & discharges (55% v8%) compared to HCQ https://t.co/sTqYHMNOGG